Meeting
2020 Gastrointestinal Cancers Symposium
Survival impact on regorafenib (REG) and trifluridine/tipiracil hydrochloride (FTD/TPI) for patients with metastatic colorectal cancer: Single institutional experience.
Authors
Keigo Chida
National Cancer Center Hospital East, Chiba, Japan
Keigo Chida , Daisuke Kotani , Kentaro Sawada , Yoshiaki Nakamura , Akihito Kawazoe , Yasutoshi Kuboki , Kohei Shitara , Takashi Kojima , Hiroya Taniguchi , Takayuki Yoshino
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 43)
Abstract #
43
Poster Bd #
B15
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
FRESCO-2: A global phase III study of the efficacy and safety of fruquintinib in patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Arvind Dasari
Poster
2016 Gastrointestinal Cancers Symposium
MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Heinz-Josef Lenz
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Sidedness and addition of chemotherapy associated with treatment outcomes of regorafenib for metastatic colorectal cancer (mCRC).
First Author: Tsung-Che Wu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Multicenter retrospective study of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) for vulnerable patients with pretreated metastatic colorectal cancer (mCRC): WJOG14520G (TWILIGHT).
First Author: Seiichiro Mitani